Makale Arama

İn this retropective study, patients with atherosclerotic risk factors and the related clinical diagnosis, angiographic scoring and regional distribution were investigated. A total of 630 patients (450 male, 180 female, mean age 56,2 ± 9.3) t hat underwent coronary angiography were enrolled. Patients were classified according to the clinical characteristic and Reardon’s modified severity scoring which is the indicator of the extend of coronary artery disease, was calculated. A parallel increase in coronary disease along with higher triglicehdes was observed, which was significantly different betvveen single and double vessel disease(p<0,05). The same correlation was apparent between HDL levels and the extent of the disease vvhich was remarkable in single and triple vessel disease group (p<0,05). Triglyceride levels varied as higher in males younger than 60 year of age vvhile smoking was lower in the same group (p<0,05). On the other hand hypertension was observed more frequently in elder patients (<60 year of age) (p<0,05). As a conclusion, ali risk factors other than smoking appeared to be higher than TEKHARF cohort, which were given for Central Anatolia region.

Aim: To assess the optimum efficacy and neurological side effect(s) of antihyperlipidemic drug regimens in dyslipidemic adult patients. Material and Method: Fotry-two male, eighty-seven female; totally 129 dyslipidemic patients, 37 to 77 years of age who admitted to neurology and cardiology out-patient clinics were eligible for our study. All of the patients were recommended to reach an ideal body weight and to maintain a standard low-lipid diet. Patients were divided into 5 subgroups and were assigned to receive commonly used antihyperlipidemic agents; low-dose atorvastatin (10 mg), pravastatin (10 mg), simvastatin (10 mg), fenofibrate (200 mg) and a combination of fenofibrate and atorvastatin regimen. Neurological examination was evaluated besides fasting plasma lipid profile and muscle enzyme levels at 0, 3, 6 and 12-month intervals. Electroneuromyography (ENMG) was performed in patients having neurological complaint(s), finding(s) and/or elevated muscle enzyme levels after drug administration. Results: According to ATP III criteria, in the second 6-month period, fenofibrate effectively improved the triglyceride profile in patients with high and borderline plasma lipid levels versus pravastatin therapy. In the first 3-month period, atorvastatin significanty improved LDL-C levels versus fenofibrate. In the first 6-month period, pravastatin caused a marked elevation of creatinine kinase levels versus atorvastatin. Among all the drugs, no other differences were observed either on lipid or on side effect profiles. No pathological findings were observed in patients who underwent ENMG. Conclusion: For the first year, low-dose antihyperlidemic agents have mostly similar efficacy profiles. Encountered side effects are; myalgia and elevated serum creatinine phosphokinase (CPK) levels at a range of 4-68 %. CPK elevations did not exceed to 3 to 10 times as reported in the literature with any of the drugs. In spite of myopathic changes in ENMG, myalgia was commonly reported. In conclusion we suggest that, patients at hig-risk, represent a suitable group for prolonged statin treatment with regular clinical follow-up.

Aim: The aim of this study was to contribute to the data about the ischemic stroke epidemiology. Material and method: We analyzed 99 patients with ischemic stroke regarding the stroke risk factors. The patients and the controls were compared in respect to stroke risk factors. Results: Hypertension, atrial fibrillation, and cigarette smoking was statistically significant as a risk factor in the stroke group compared with the control group (P<0.05). Conclusion: Diabetes mellitus and dyslipidemia have not been found as significant risk factors in patients with stroke when compared with the control group (P>0.05).

Backround: Myocardial infarction with coronary artery disease (MICAD) is the leading cause of myocardial injury. Myocardial injury non-related to atherosclerotic plaque disruption (non-MICAD) is a rare and heterogeneous diagnosis. Although MICAD is well studied, non-MICAD was not thoroughly identified in young patient population. We aimed to investigate the frequency, main etiologies, and five-year mortality of patients with non-MICAD younger than 40 years.

Methods: We retrospectively enrolled 292 patients with acute myocardial injury younger than 40 years between January 2010 and December 2014. Clinical, demographic, laboratory, angiographic features, and five-year all-cause mortality were compared between patients with non-MICAD (n=78) and MICAD (n=214).

Results: Median age of patients was 36. Non-MICAD group was younger than MICAD group [32 (28-37) vs 37 (34-39)]. The frequency of female patients with non-MICAD was higher than those with MICAD (24.4% vs 10.3%). Most of the patients with MICAD presented with STEMI (77.1%), while most of the patients with non-MICAD presented with non-STEMI (89.7%). Most common etiologies of non-MICAD in were myocarditis (32%) and vasospasm (9%). Age, female sex, no smoking and, absence of dyslipidemia were independent predictors for non-MICAD. Five-year all-cause mortality in non-MICAD group was significantly lower than MICAD group (2.6% vs 10.3%) (log-rank test p=0.04).

Conclusion: Non-MICAD represents a heterogeneous group of patients who had varying etiologies at different ages. Despite the lower mortality rate of non-MICAD group, different diagnostic and treatment strategies are required for management of patients with non-MICAD.